The Lipodystrophy Syndrome as a Risk Marker for Cardiovascular Disease in Patients with HIV/AIDS Treated with HAART

Authors

  • Valdelias Xavier Pereira
  • Luiz Carlos de Abreu Faculdade de Medicina do ABC. Departamento de Saúde da Coletividade. Disciplina de Metodologia Científica.
  • Vitor Engrácia Valenti
  • Rodrigo Daminello Raimundo
  • Mariliza Henrique Silva
  • Fernando Rocha Oliveira
  • Renata Salatini
  • Adriano Luiz Roque
  • Marcia de Toledo Blake
  • Marcia de Toledo Blake
  • Erick Silva Dias
  • Celso Ferreira Filho
  • Vivian Finotti
  • Celso Ferreira

DOI:

https://doi.org/10.3823/1677

Keywords:

HIV, Lipodystrophy syndrome, cardiovascular disease, AIDS

Abstract

Introduction: The classic risk factors for cardiovascular disease in healthy individuals are well known, however, it lacks in the literature the mechanisms that predicts cardiovascular disease in the population living with HIV-AIDS treated with HAART and presenting syndrome lipodystrophy. We aimed to investigate the risk of cardiovascular disease in HIV-AIDS patients treated with HAART and lipodystrophy syndrome. Methods: A search was performed in Medline, SciELO, Lilacs and Cochrane using the intersection between the keywords: "cardiovascular disease", "HIV", "AIDS", "HAART" and "lipodystrophy syndrome". Results: The selected studies demonstrated that metabolic disorders such as hyperlipidemia, central adipose hypertrophy and peripheral lipoatrophy, besides the metabolic syndrome and lipodystrophy are maker clear risks of developing cardiovascular disease in these individuals. Conclusion: The metabolic alterations in HIV-AIDS treated with HAART and presenting lipodystrophy syndrome may potentiate the development of cardiovascular diseases.

References

Center for Disease Control and Prevention. Pneumocystis pneumonia - Los Angeles. Morbid Mortal Wkly Repor. 1981;30:250-2.

Center for Disease Control and Prevention. Kaposi's Sarcoma and Pneumocycstis Pneumonia Among Homosexual Men - New York City and California. Morbid Mortal Wkly Repor. 1981;30:305-8.

Sabino EC, Barreto CC, Sanabani S. AIDS: Etiologia e Subtipos do HIV. In: Veronesi R, Focaccia R, editores. Tratado de infectologia. São Paulo: theneu; 2005. p. 111-7.

Soares FMG, and Costa, IMC. Lipoatrofia facial associada ao HIV/AIDS: do advento aos conhecimentos atuais. An. Bras. Dermatol. 2011; p. 843-864.

Marques AR, Masur H. História Natural da Infecção pelo HIV. In: Veronesi R, Focaccia R, editores científicos. Tratado de infectologia. São Paulo: Atheneu; 2005. p.143-6.

Sadala MLA, Marques AS. Vinte anos de assistência a pessoas vivendo com HIV/aids no Brasil: a perspectiva de profissionais de saúde. Cad Saúde Publ. 2006;22:2369-78.

Brasil. Ministério da Saúde. Fundação Nacional de Saúde. Guia de Vigilância Epidemiológica. 5. ed. Brasília: Funasa; 20012. 842 p. (Aids/Hepatites Virais; vol. 1).

Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de DST, AIDS e Hepatites Virais. Manual de tratamento da lipoatrofia facial: recomendações para o preenchimento facial com polimetilmetacrilato em portadores de HIV/AIDS. Série A. Normas e Manuais Técnicos. Série Manuais 81. Brasília: Ministério da Saúde; 2009. 44 p.

Brasil. Ministério da Saúde. Secretaria de Assistência a Saúde. Programa Nacional de DST/Aids. Consenso sobre a terapia anti-retroviral em adultos. Brasília: Ministério da Saúde; 1996.

Lomar AV, Diament D. Terapia Anti-retroviral. In: Veronesi R, Focaccia R, editores científicos. Tratado de infectologia. São Paulo: Atheneu; 2005.

Martinez E, Mocroft A, García-Viejo MA, Pérez-Cuevas JB, Blanco JL, Mallolas J, et al. Risk of Lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357:592-8.

Piloya T et al. Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study. Journal of the International AIDS Society 2012, 15:17427.

Lenhard JM, Furfine ES, Jain RG, et al. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antiviral Res 2000;47:121-129.

Steven G, and Andrew C. Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults. N Engl J Med 2005; 352:48-62.

Caron M, Auclair M, Sterlingot H, Kornprobst M, Capeau J. Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS 2003;17:2437-2444.

Hadigan C, Borgonha S, Rabe J, Young V, Grinspoon S. Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy. Metabolism 2010;51:1143-1147.

Roche R, Poizot-Martin I, Yazidi CM, et al. Effects of antiretroviral drug combinations on the differentiation of adipocytes. AIDS 2012;16:13-20.

Galli M, Veglia F, Angarano G, et al. Gender differences in antiretroviral drug-related adipose tissue alterations: women are at higher risk than men and develop particular lipodystrophy patterns. J Acquir Immune Defic Syndr 2003;34:58-61.

Sutinen J, Hakkinen AM, Westerbacka J, et al. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 2012;16:2183-2193.

Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003;348:702-710.

Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003;17:2479-2486.

Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003;33:506-512.

The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003.

d'Arminio A, Sabin CA, Phillips AN, et al. Cardio- and Cerebrovascular Events in HIV-infected Persons. AIDS 2004;18:1811-1817.

Dressman J, Kincer J, Matveev SV, et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J Clin Invest 2003;111:389-397.

Law MG, D'Arminio Monforte A, Friis-Moller N, et al. Cardio- and cerebrovascular events and predicted rates of myocardial infarction in the D:A:D: study. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8–11, 2004:737.

Downloads

Published

2015-04-20

Issue

Vol. 8 (2015)

Section

Cardiology

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access and Benefits of Publishing Open Access).

 

 

Most read articles by the same author(s)

1 2 3 4 > >>